🇪🇺 Paliperidone, LAI in European Union

EMA authorised Paliperidone, LAI on 24 June 2007

Marketing authorisation

EMA — authorised 24 June 2007

  • Application: EMEA/H/C/000746
  • Marketing authorisation holder: Janssen-Cilag International NV
  • Local brand name: Invega
  • Indication: Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older. Invega is indicated for the treatment of schizoaffective disorder in adults.
  • Status: approved

Read official source →

Frequently asked questions

Is Paliperidone, LAI approved in European Union?

Yes. EMA authorised it on 24 June 2007.

Who is the marketing authorisation holder for Paliperidone, LAI in European Union?

Janssen-Cilag International NV holds the EU marketing authorisation.